Finland· FI-REL-REL59228
Calquence
A acalabrutinib product containing acalabrutinib maleate, registered in Finland by AstraZeneca AB. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Acalabrutinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EL02 (acalabrutinib), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Acalabrutinib · ATC L01EL02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of acalabrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $190.74 in Switzerland — a ×1172 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Acalabrutinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$190.74
- FR France$0.16
The record
At a glance
Fimea (Finland)- Active substance
- Acalabrutinib maleate
- Manufacturer
- AstraZeneca AB
- Country
- Finland (FI)
- ATC code
- L01EL02
- ATC class
- Acalabrutinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa09827660EUR 5860.32
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
375 interactions on record for acalabrutinib.
Graded by severity as the source publishes them — 201 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acalabrutinib · interactions on record
375 records
- 201 severe
- 174 moderate
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Acalabrutinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCALQUENCE 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- CzechiaCALQUENCEAstraZeneca AB, Södertälje
- United StatesCALQUENCEAstraZeneca Pharmaceuticals LP
- BelgiumCalquence 100 mgAstraZeneca
- NetherlandsCalquence 100 mg, filmomhulde tablettenAstraZeneca AB
- NorwayCalquenceAstraZeneca AB
- PolandCalquenceAstraZeneca AB
- SwedenCalquence 100 mg Filmdragerad tablettAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Calquence
- Liechtenstein · Calquence
- Norway · Calquence
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a4d0a013-6401-42b5-9060-94f807d8027c GET /v1/drugs/a4d0a013-6401-42b5-9060-94f807d8027c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.2",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "g",
"strength": "100 mg",
"atc_label": "akalabrutinibi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/20/1479/003-004",
"fimea_rel_id": "REL59228",
"authorised_at": "2023-02-20"
}See everything about acalabrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.